Allogeneic hematopoietic cell transplant (HCT) in patients (pts) ≥ 60 years of age with first relapsed or refractory acute myeloid leukemia (R/R AML) after treatment with vosaroxin plus cytarabine (vos/cyt) vs placebo plus cytarabine (pla/cyt): Results from VALOR Meeting Abstract
| Authors: | Schiller, G. J.; Ritchie, E. K.; Sayar, H.; Lancet, J. E.; Craig, M. D.; Vey, N.; Strickland, S. A.; Erba, H. P.; Pigneux, A.; Horst, H. A.; Recher, C.; Klimek, V. M.; Odenike, O.; Craig, A. R.; Ward, R.; Smith, J.; Kantarjian, H. M.; Stuart, R. K.; Ravandi, F. |
| Abstract Title: | Allogeneic hematopoietic cell transplant (HCT) in patients (pts) ≥ 60 years of age with first relapsed or refractory acute myeloid leukemia (R/R AML) after treatment with vosaroxin plus cytarabine (vos/cyt) vs placebo plus cytarabine (pla/cyt): Results from VALOR |
| Meeting Title: | 51st Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 33 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2015 May 29-Jun 2 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2015-05-20 |
| Language: | English |
| ACCESSION: | WOS:000358036901591 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2015.33.15_suppl.7055 |
| Notes: | Meeting Abstract: 7055 -- Source: Wos |
